Description: TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Home Page: www.tmepharma.com
Max-Dohrn-Strasse 8-10
Berlin,
10589
Germany
Phone:
49 30 726247 0
Officers
| Name | Title |
|---|---|
| Dr. Aram Mangasarian Ph.D. | CEO & Member of Management Board |
| Mr. Bryan Jennings | CFO & Member of Management Board |
| Ewelina Staniuk | Sr. Director of Investor Relations & Bus. Devel. |
| Karen Ophoff | VP of Legal & Gen. Counsel |
| Dr. Jarl Ulf Jungnelius M.D., Ph.D. | Sr. Medical Advisor & Chief Medical Officer |
| Heike Balzer | Sr. VP of Fin. |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.0715 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9113 |
| Price-to-Sales TTM: | 61.4686 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |